Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 17/20 | 0.48 |
| ▸ | PARP2 | Q9UGN5 | 6/20 | 0.48 |
| ▸ | HTR1A | P08908 | 2/20 | 0.45 |
| ▸ | DRD2 | P14416 | 2/20 | 0.45 |
| ▸ | HTR7 | P34969 | 2/20 | 0.45 |
| ▸ | HRH1 | P35367 | 2/20 | 0.45 |
| ▸ | DRD3 | P35462 | 2/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6964340 | 0.85 | PARP1 (0.53) | PARP1PARP2 | |
| SCHEMBL6841121 | 0.82 | PARP1 (0.56) | PARP1PARP2 | |
| SCHEMBL6836856 | 0.72 | PARP1 (0.51) | PARP1PARP2 | |
| SCHEMBL6841975 | 0.70 | RIPK1 (0.43) | PARP1 | |
| SCHEMBL6842034 | 0.69 | PARP1 (0.50) | PARP1PARP2 | |
| SCHEMBL25022851 | 0.68 | PARP1 (0.63) | PARP1PARP2 | |
| SCHEMBL6841122 | 0.67 | PARP1 (0.61) | PARP1PARP2 | |
| SCHEMBL23581692 | 0.67 | PARP1 (0.66) | PARP1 | |
| SCHEMBL6841485 | 0.67 | PARP1 (0.58) | PARP1PARP2 | |
| SCHEMBL6836940 | 0.67 | PARP1 (0.58) | PARP1PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040209933-A1 | Oxazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2004-10-21 | — | — | US | disclosed |
| US-20040034078-A1 | Benzimidazole inhibitors of poly(ADP-ribosyl) polymerase | AGOURON PHARMACEUTICALS, INC. | 2004-02-19 | — | — | US | disclosed |
| WO-2003106430-A1 | BENZIMIDAZOLE INHIBITORS OF POLY(ADP-RIBOSYL) POLYMERASE | PFIZER INC. (US) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209933-A1 | Oxazole derivatives | OXA1L, SULT1E1, CYP3A7 | PARP1 1988/4885PARP2 2117/4885HTR1A 4131/4885 |
| US-20040034078-A1 | Benzimidazole inhibitors of poly(ADP-ribosyl) polymerase | PARP1, PARP11, PARP2 | PARP1 1/4885PARP2 3/4885HTR1A 2075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.